1 / 4

Blinatumomab: A Bispecific CD19-directed CD3 T-cell Engager

Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that is known to bind to CD19 (expressed on cells of B-lineage origin) and CD3 (expressed on the T-cells). The blinatumomab price in India can fluctuate depending on different factors. In order to procure blinatumomab, kindly get in touch with us at TOLL-FREE: 1800-889-1064. This medication is authorized as a second-line treatment for Philadelphia chromosome -Ve relapsed or refractory acute lymphoblastic leukemia (ALL). We're the leading supplier of blinatumomab, based in India.

amitsharma2020
Download Presentation

Blinatumomab: A Bispecific CD19-directed CD3 T-cell Engager

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BLINCYTO® (blinatumomab) Injection ACUTE LYMPHOBLASTIC ACUTE LYMPHOBLASTIC LEUKEMIA LEUKEMIA

  2. Blincyto Common Side Effects • Fever • Headache • Swelling of the extremities. • Nausea • Tremor • Rash

  3. Blinatumomab is a type of immunotherapy known as a Bispecific T cell Engager molecule (also known as a BiTE), used to treat B-cell precursor ALL (acute lymphoblastic leukemia) in patients who still have detectable traces of cancer folowing chemotherapy. It is also used to treat a certain sort of acute lymphoblastic leukemia (ALL) in adults and children. Acute lymphoblastic leukemia is a cancer of the blood and bone marrow in which a specific kind of WBC is replicating in uncontrolled way. This immunotherapy medicine is supplied in a single-dose vial as a sterile, preservative-free, white-off-white lyophilized powder for intravenous (IV) administration. Do not drive, or operate any heavy machinery, or do other dangerous activities during therapy with Blinatumomab because the drug can be responsible for causing neurological signs and symptoms, such as seizures, dizziness, and confusion. BLINCYTO INJECTION FOR ACUTE LYMPHOBLASTIC LEUKEMIA

More Related